Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mark J Roschewski, M.D.
National Cancer Institute (NCI)
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Holy Cross Hospital, Fort Lauderdale
Fort Lauderdale, Florida, United States
- University of Maryland, Baltimore
Baltimore, Maryland, United States
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
- Brigham and Women'S Hospital
Boston, Massachusetts, United States
- St. Luke'S Roosevelt Hospital
New York, New York, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 8 May 1993
- Primary completion
- 24 May 2024
- Completion
- 24 May 2024
- Last update posted
- 22 Jun 2025
- Registered enrollment
- 348
- Registry id
- NCT00001337
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.